Review





Similar Products

94
Bioss tlr2 polyclonal antibody
Tlr2 Polyclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/custom%40bs-1019r%4042569198?v=Bioss
Average 94 stars, based on 1 article reviews
tlr2 polyclonal antibody - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
InvivoGen mab mtlr2 anti mouse human tlr2
<t>TLR2</t> is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.
Mab Mtlr2 Anti Mouse Human Tlr2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pmc13186032-18-0-5?v=InvivoGen
Average 94 stars, based on 1 article reviews
mab mtlr2 anti mouse human tlr2 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
MedChemExpress c29
<t>TLR2</t> is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.
C29, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pm42209521-1482-17-22?v=MedChemExpress
Average 94 stars, based on 1 article reviews
c29 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

95
InvivoGen tlr2 signaling inhibitor tl2 c29
Hemoglobin mediates gene repression through <t>TLR2</t> and TLR4 (A and B) A study was conducted to determine the effect of hemoglobin (Hb) on (A) fibroblast-to-cardiomyocyte reprogramming and (B) fibroblast gene expression. With respect to fibroblast-to-cardiomyocyte reprogramming, cardiac fibroblasts were transfected with either miR combo or a non-targeting control miR. 24 h later, the cells were incubated with vehicle, a TLR2 pharmacological inhibitor, a TLR4 pharmacological inhibitor, or a combination of both pharmacological inhibitors for 3 h. After incubation with the indicated pharmacological inhibitors, Hb was added (5 mg/mL) to the media. All media was replaced the next day. Fourteen days after miR transfection, cells were analyzed for expression of the indicated cardiomyocyte specific genes by qPCR. Expression values were normalized to the housekeeping gene Gapdh. N = 6–10. One-sample t tests were used to compare groups to the control group (∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; ns, not significant). t test was used to determine the significance between the miR combo groups (## p < 0.01, # p < 0.05; ns, not significant). With respect to fibroblast gene expression, cardiac fibroblasts were incubated with vehicle, a TLR2 pharmacological inhibitor, a TLR4 pharmacological inhibitor, or a combination of both pharmacological inhibitors for 3 h. After incubation with the indicated pharmacological inhibitors, Hb was added (5 mg/mL) to the media. All media was replaced the next day. Expression of the indicated fibroblast-specific genes was determined by qPCR and normalized to the housekeeping gene Gapdh. N = 10. One-sample t tests were used to compare groups to the control group (∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; ns, not significant).
Tlr2 Signaling Inhibitor Tl2 C29, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pmc13049640-295-4-7?v=InvivoGen
Average 95 stars, based on 1 article reviews
tlr2 signaling inhibitor tl2 c29 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

86
Huabio Inc tlr2
Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 <t>(TLR2),</t> integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.
Tlr2, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pmc13198320-383-13-19?v=Huabio+Inc
Average 86 stars, based on 1 article reviews
tlr2 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

99
InvivoGen tlr2 agonist pam3csk4
Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 <t>(TLR2),</t> integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.
Tlr2 Agonist Pam3csk4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pm42177887-63-1-16?v=InvivoGen
Average 99 stars, based on 1 article reviews
tlr2 agonist pam3csk4 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

97
MedChemExpress tlr2 inhibitor c29
Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 <t>(TLR2),</t> integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.
Tlr2 Inhibitor C29, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pm42177887-64-1-8?v=MedChemExpress
Average 97 stars, based on 1 article reviews
tlr2 inhibitor c29 - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

86
Huabio Inc tlr2 antibody
Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 <t>(TLR2),</t> integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.
Tlr2 Antibody, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pm42144065-74-1-12?v=Huabio+Inc
Average 86 stars, based on 1 article reviews
tlr2 antibody - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

96
InvivoGen pam2csk4 tlr2 tlr6 agonist
Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 <t>(TLR2),</t> integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.
Pam2csk4 Tlr2 Tlr6 Agonist, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pmc13127319-17-0-5?v=InvivoGen
Average 96 stars, based on 1 article reviews
pam2csk4 tlr2 tlr6 agonist - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

95
InvivoGen tlr2 inhibitor tl2 c29
Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 <t>(TLR2),</t> integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.
Tlr2 Inhibitor Tl2 C29, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr2/pm42140967-273-171-175?v=InvivoGen
Average 95 stars, based on 1 article reviews
tlr2 inhibitor tl2 c29 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


TLR2 is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.

Journal: iScience

Article Title: cGAS/STING sensing in dendritic cells discriminates between daptomycin sensitive and resistant Staphylococcus aureus clinical isolates

doi: 10.1016/j.isci.2026.115854

Figure Lengend Snippet: TLR2 is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.

Article Snippet: mAB mTLR2- anti-mouse/human TLR2 , InvivoGen , Cat# mab-mtlr2; RRID: AB_763722.

Techniques: Labeling, Blocking Assay, Control, Expressing, Activation Assay, Marker

Hemoglobin mediates gene repression through TLR2 and TLR4 (A and B) A study was conducted to determine the effect of hemoglobin (Hb) on (A) fibroblast-to-cardiomyocyte reprogramming and (B) fibroblast gene expression. With respect to fibroblast-to-cardiomyocyte reprogramming, cardiac fibroblasts were transfected with either miR combo or a non-targeting control miR. 24 h later, the cells were incubated with vehicle, a TLR2 pharmacological inhibitor, a TLR4 pharmacological inhibitor, or a combination of both pharmacological inhibitors for 3 h. After incubation with the indicated pharmacological inhibitors, Hb was added (5 mg/mL) to the media. All media was replaced the next day. Fourteen days after miR transfection, cells were analyzed for expression of the indicated cardiomyocyte specific genes by qPCR. Expression values were normalized to the housekeeping gene Gapdh. N = 6–10. One-sample t tests were used to compare groups to the control group (∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; ns, not significant). t test was used to determine the significance between the miR combo groups (## p < 0.01, # p < 0.05; ns, not significant). With respect to fibroblast gene expression, cardiac fibroblasts were incubated with vehicle, a TLR2 pharmacological inhibitor, a TLR4 pharmacological inhibitor, or a combination of both pharmacological inhibitors for 3 h. After incubation with the indicated pharmacological inhibitors, Hb was added (5 mg/mL) to the media. All media was replaced the next day. Expression of the indicated fibroblast-specific genes was determined by qPCR and normalized to the housekeeping gene Gapdh. N = 10. One-sample t tests were used to compare groups to the control group (∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; ns, not significant).

Journal: Molecular Therapy. Nucleic Acids

Article Title: Hemoglobin inhibits fibroblast-to-cardiomyocyte reprogramming via TLR2/TLR4-dependent chromatin compaction

doi: 10.1016/j.omtn.2026.102900

Figure Lengend Snippet: Hemoglobin mediates gene repression through TLR2 and TLR4 (A and B) A study was conducted to determine the effect of hemoglobin (Hb) on (A) fibroblast-to-cardiomyocyte reprogramming and (B) fibroblast gene expression. With respect to fibroblast-to-cardiomyocyte reprogramming, cardiac fibroblasts were transfected with either miR combo or a non-targeting control miR. 24 h later, the cells were incubated with vehicle, a TLR2 pharmacological inhibitor, a TLR4 pharmacological inhibitor, or a combination of both pharmacological inhibitors for 3 h. After incubation with the indicated pharmacological inhibitors, Hb was added (5 mg/mL) to the media. All media was replaced the next day. Fourteen days after miR transfection, cells were analyzed for expression of the indicated cardiomyocyte specific genes by qPCR. Expression values were normalized to the housekeeping gene Gapdh. N = 6–10. One-sample t tests were used to compare groups to the control group (∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; ns, not significant). t test was used to determine the significance between the miR combo groups (## p < 0.01, # p < 0.05; ns, not significant). With respect to fibroblast gene expression, cardiac fibroblasts were incubated with vehicle, a TLR2 pharmacological inhibitor, a TLR4 pharmacological inhibitor, or a combination of both pharmacological inhibitors for 3 h. After incubation with the indicated pharmacological inhibitors, Hb was added (5 mg/mL) to the media. All media was replaced the next day. Expression of the indicated fibroblast-specific genes was determined by qPCR and normalized to the housekeeping gene Gapdh. N = 10. One-sample t tests were used to compare groups to the control group (∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05; ns, not significant).

Article Snippet: Hb (Millipore Sigma, H2625), TLR2 signaling inhibitor-TL2-C29 (InvivoGen, catalog no. inh-c29), and TLR4 inhibitor-CLI-095 (InvivoGen, catalog no. tlrl-cli95-4) were used.

Techniques: Gene Expression, Transfection, Control, Incubation, Expressing

Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 (TLR2), integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.

Journal: Cell Reports Medicine

Article Title: Macrophage-mimetic photothermal nanotherapeutics regulate mitochondrial homeostasis and inflammatory cascades in lung ischemia-reperfusion injury

doi: 10.1016/j.xcrm.2026.102768

Figure Lengend Snippet: Preparation and characterization of Rg3@PACVs (A–C) Characterization of mPDA, Rg3@mPDA, and Rg3@PACVs using transmission electron microscopy (TEM) and dynamic light scattering (DLS) for hydrodynamic size distribution and zeta potential analysis (scale bars, 100 nm). (D) Elemental mapping of carbon (C), nitrogen (N), oxygen (O), phosphorus (P), and sulfur (S) in Rg3@PACVs (scale bars, 100 nm). (E) Fourier transform infrared spectroscopy (FTIR) spectra of mPDA, Rg3, Mac-CVs, and Rg3@PACVs. (F) The expression of macrophage-membrane markers including Toll-like receptor 2 (TLR2), integrin subunit alpha M (CD11b), C-X-C motif chemokine receptor 4 (CXCR4), receptor for advanced glycation end-products (RAGE), interleukin-6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1) detected by digital western blot analysis. (G) Fluorescence of Dio-labeled Mac-CVs and Dil-labeled Rg3@mPDA after ultrasonic extrusion to form Dio/Dil-labeled Rg3@PACVs (scale bars, 1 μm). (H) Near-infrared (NIR, 808nm) images of Rg3, mPDA, Mac-CVs, and Rg3@PACVs in microcentrifuge tubes. (I and J) Temperature changes of Rg3@PACVs under different laser power intensities (I) and the photothermal effect curves of Rg3@PACVs at various concentrations (J). (K) Photothermal stability of Rg3@PACVs. (L) Size stability of Rg3@PACVs after 1-week storage at 4°C and 37°C.

Article Snippet: The target proteins included CD11b (HA722075, HUABIO, China), CXCR4 ( AWA46731 ,Abiowell, China), TLR2 (52945,Genuin Biotech, China), RAGE (ET1702-27, HUABIO), IL-6R ( AWA43078 , Abiowell), Na + /K + -ATPase (RT1412, HUABIO), PGC-1α ( AWA59146 , Abiowell), MFN2 (CSB-RA139716A0HU, CUSABIO, China), DRP1 ( HA500487 , HUABIO), phosphorylated DRP1 (Ser616) (PSH06-77, HUABIO), PI3K (Genuin Biotech), phosphorylated PI3K (U1011, Genuin Biotech), Akt (ET1609-51, HUABIO), and phosphorylated Akt (ET1607-73, HUABIO) and β-actin (EM21002, HUABIO).

Techniques: Transmission Assay, Electron Microscopy, Zeta Potential Analyzer, Fourier Transform Infrared Spectroscopy, Spectroscopy, Expressing, Membrane, Western Blot, Fluorescence, Labeling

Journal: Cell Reports Medicine

Article Title: Macrophage-mimetic photothermal nanotherapeutics regulate mitochondrial homeostasis and inflammatory cascades in lung ischemia-reperfusion injury

doi: 10.1016/j.xcrm.2026.102768

Figure Lengend Snippet:

Article Snippet: The target proteins included CD11b (HA722075, HUABIO, China), CXCR4 ( AWA46731 ,Abiowell, China), TLR2 (52945,Genuin Biotech, China), RAGE (ET1702-27, HUABIO), IL-6R ( AWA43078 , Abiowell), Na + /K + -ATPase (RT1412, HUABIO), PGC-1α ( AWA59146 , Abiowell), MFN2 (CSB-RA139716A0HU, CUSABIO, China), DRP1 ( HA500487 , HUABIO), phosphorylated DRP1 (Ser616) (PSH06-77, HUABIO), PI3K (Genuin Biotech), phosphorylated PI3K (U1011, Genuin Biotech), Akt (ET1609-51, HUABIO), and phosphorylated Akt (ET1607-73, HUABIO) and β-actin (EM21002, HUABIO).

Techniques: Recombinant, Purification, Marker, Isolation, Enzyme-linked Immunosorbent Assay, CCK-8 Assay, Apoptosis Assay, Membrane, Fluorescence, Sequencing, Gene Expression, Western Blot, Software, Real-time Polymerase Chain Reaction, Microscopy, Flow Cytometry